Sophia Genetics Sa Financials
Sophia Genetics Sa (SOPH) reported $77.3M in revenue for fiscal year 2025, up 18.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling faster than cash burn, but equity erosion and a thinner liquidity cushion show the model still needs financing.
The least obvious shift is that FY2025 looked worse on earnings but better on cash: net loss widened from-$62.5M to-$79.0M , yet operating cash outflow still narrowed from FY2024. With capex at only$574K and free cash flow staying close to operating cash flow, this is a low-capital-intensity business whose recent improvement came more from cash discipline than from a true profit turn.
From FY2022 to FY2025, cash burn efficiency improved sharply: free-cash-flow margin moved from
The short-term cushion thinned quickly in FY2025 as cash slipped to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sophia Genetics Sa's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Sophia Genetics Sa, and counted as zero in the overall score.
Sophia Genetics Sa passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Sophia Genetics Sa reported a net loss of $79.0M while operations used $35.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Sophia Genetics Sa generated $77.3M in revenue in fiscal year 2025. This represents an increase of 18.6% from the prior year.
Sophia Genetics Sa reported -$79.0M in net income in fiscal year 2025. This represents a decrease of 26.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Sophia Genetics Sa recorded an outflow of $36.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 18.5% from the prior year.
Sophia Genetics Sa held $70.3M in cash against $12.6M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Sophia Genetics Sa's ROE was -167.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 102.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Sophia Genetics Sa invested $574K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 135.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
SOPH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Revenue | $77.3M+18.6% | $65.2M+4.5% | $62.4M+31.1% | $47.6M+17.6% | $40.5M+42.4% | $28.4M+12.0% | $25.4M |
| Interest Expense | $573K+1.1% | $567K+4.0% | $545K+29.1% | $422K+87.6% | $225K+86.0% | $121K-6.2% | $129K |
| Income Tax | $1.5M+23.6% | $1.2M+151.6% | $486K+457.4% | -$136K-181.0% | $168K+108.9% | -$1.9M-1264.2% | $162K |
| Net Income | -$79.0M-26.4% | -$62.5M+20.9% | -$79.0M+9.7% | -$87.4M-18.7% | -$73.7M-87.3% | -$39.3M-16.4% | -$33.8M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).
SOPH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $163.0M+5.0% | $155.3M-24.7% | $206.2M-15.5% | $243.8M-23.8% | $320.2M+142.3% | $132.1M | N/A |
| Current Assets | $99.1M-0.3% | $99.4M-32.9% | $148.0M-24.6% | $196.3M-30.6% | $282.9M+157.9% | $109.7M | N/A |
| Cash & Equivalents | $70.3M-12.4% | $80.2M-34.9% | $123.3M-23.6% | $161.3M-16.4% | $193.0M+158.6% | $74.6M+313.0% | $18.1M |
| Inventory | $6.4M+8.2% | $5.9M-9.5% | $6.5M+25.7% | $5.2M-10.0% | $5.7M+69.3% | $3.4M | N/A |
| Accounts Receivable | $15.0M+101.7% | $7.4M-45.2% | $13.6M+103.9% | $6.6M+5.9% | $6.3M-1.3% | $6.4M | N/A |
| Goodwill | $35.9M+23.8% | $29.0M+6.7% | $27.2M+36.2% | $20.0M+27.4% | $15.7M+18.0% | $13.3M | N/A |
| Total Liabilities | $115.9M+97.0% | $58.8M+7.5% | $54.7M+25.2% | $43.7M-2.4% | $44.8M+41.7% | $31.6M | N/A |
| Current Liabilities | $50.5M+88.5% | $26.8M-24.8% | $35.6M+32.9% | $26.8M-6.3% | $28.6M+32.5% | $21.6M | N/A |
| Long-Term Debt | $12.6M-13.8% | $14.6M-6.8% | $15.7M+11.5% | $14.1M+25.0% | $11.2M+290.1% | $2.9M-24.9% | $3.8M |
| Total Equity | $47.1M-51.1% | $96.5M-36.3% | $151.4M-24.3% | $200.1M-27.3% | $275.4M+174.0% | $100.5M+351.7% | $22.3M |
| Retained Earnings | -$519.3M-17.9% | -$440.3M-16.5% | -$377.8M-26.4% | -$298.8M-41.4% | -$211.4M-53.5% | -$137.7M | N/A |
SOPH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$35.9M+19.4% | -$44.5M+16.4% | -$53.2M+24.1% | -$70.1M-21.0% | -$57.9M-82.6% | -$31.7M-0.2% | -$31.7M |
| Capital Expenditures | $574K+135.2% | $244K-83.7% | $1.5M-63.5% | $4.1M+52.7% | $2.7M+496.2% | $450K-66.8% | $1.4M |
| Free Cash Flow | -$36.5M+18.5% | -$44.8M+18.2% | -$54.7M+26.2% | -$74.2M-22.4% | -$60.6M-88.4% | -$32.2M+2.6% | -$33.0M |
| Investing Cash Flow | -$8.7M-82.3% | -$4.8M-136.6% | $13.0M-69.1% | $42.0M+173.7% | -$56.9M-134.1% | -$24.3M-701.9% | -$3.0M |
| Financing Cash Flow | $30.2M+206.1% | $9.9M+449.2% | -$2.8M-80.0% | -$1.6M-100.7% | $237.8M+122.1% | $107.0M+10563.8% | -$1.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SOPH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Net Margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | -138.5% | -133.2% |
| Return on Equity | -167.6%-102.8pp | -64.8%-12.6pp | -52.1%-8.4pp | -43.7%-16.9pp | -26.8%+12.4pp | -39.1%+112.7pp | -151.8% |
| Return on Assets | -48.5%-8.2pp | -40.2%-1.9pp | -38.3%-2.5pp | -35.9%-12.8pp | -23.0%+6.8pp | -29.8% | N/A |
| Current Ratio | 1.96-1.7x | 3.71-0.4x | 4.16-3.2x | 7.32-2.6x | 9.89+4.8x | 5.08 | N/A |
| Debt-to-Equity | 0.27+0.1x | 0.150.0x | 0.100.0x | 0.070.0x | 0.040.0x | 0.03-0.1x | 0.17 |
| FCF Margin | -47.2%+21.5pp | -68.7%+19.1pp | -87.7% | -156.0% | -149.9% | -113.3% | -130.3% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Where Sophia Genetics Sa Ranks
Frequently Asked Questions
What is Sophia Genetics Sa's annual revenue?
Sophia Genetics Sa (SOPH) reported $77.3M in total revenue for fiscal year 2025. This represents a 18.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sophia Genetics Sa's revenue growing?
Sophia Genetics Sa (SOPH) revenue grew by 18.6% year-over-year, from $65.2M to $77.3M in fiscal year 2025.
Is Sophia Genetics Sa profitable?
No, Sophia Genetics Sa (SOPH) reported a net income of -$79.0M in fiscal year 2025.
How much debt does Sophia Genetics Sa have?
As of fiscal year 2025, Sophia Genetics Sa (SOPH) had $70.3M in cash and equivalents against $12.6M in long-term debt.
What is Sophia Genetics Sa's return on equity (ROE)?
Sophia Genetics Sa (SOPH) has a return on equity of -167.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sophia Genetics Sa's free cash flow?
Sophia Genetics Sa (SOPH) recorded an outflow of $36.5M in free cash flow during fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sophia Genetics Sa's operating cash flow?
Sophia Genetics Sa (SOPH) recorded an outflow of $35.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sophia Genetics Sa's total assets?
Sophia Genetics Sa (SOPH) had $163.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sophia Genetics Sa's capital expenditures?
Sophia Genetics Sa (SOPH) invested $574K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Sophia Genetics Sa's current ratio?
Sophia Genetics Sa (SOPH) had a current ratio of 1.96 as of fiscal year 2025, which is generally considered healthy.
What is Sophia Genetics Sa's debt-to-equity ratio?
Sophia Genetics Sa (SOPH) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sophia Genetics Sa's return on assets (ROA)?
Sophia Genetics Sa (SOPH) had a return on assets of -48.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sophia Genetics Sa's cash runway?
Based on fiscal year 2025 data, Sophia Genetics Sa (SOPH) had $70.3M in cash against an annual operating cash burn of $35.9M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sophia Genetics Sa's Piotroski F-Score?
Sophia Genetics Sa (SOPH) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sophia Genetics Sa's earnings high quality?
Sophia Genetics Sa (SOPH) reported a net loss of $79.0M while operations used $35.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Sophia Genetics Sa?
Sophia Genetics Sa (SOPH) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.